Eton Pharmaceuticals, Inc.

Good afternoon and welcome to Eaton Pharmaceuticals' second quarter 2020 financial and operating results conference call. At this time, all participants are in the listen-only mode. Following the formal remarks, we will open the call up for your questions. Please be advised that this call is being recorded at the company's request. At this time, I'd like to turn the call over to David Krempa, Vice President of Business Development at Eaton Pharmaceuticals.

Please proceed. Thank you, operator.

Good afternoon, everyone, and welcome to Eaton's second quarter 2020 conference call. This afternoon, we issued a press release that outlines the topics we plan to discuss on today's call. The release is available on our website, EatonPharma.com. Joining me on our call today, we have Sean Brynjelsen, our CEO, Wilson Troutman, our CFO, and Paul Stickler, our Senior Vice President of Sales and Marketing. Before we begin, I would like to remind everyone that statements made during this call may contain forward-looking statements and involve risks and uncertainties that could cause actual results to differ materially from those contained in these forward-looking statements. Please see the forward-looking statement's disclaimer in our earnings release and the risk factors in the company's filings with the SEC. Now, I will turn the call over to our CEO, Sean Brynjelsen.